All of the negative comments about daraxonrasib center around how it’s not a “cure” for pancreatic cancer. For the longest time, we’ve dealt with a substandard therapy-chemotherapy; and watched our patients succumb to this awful disease. On RASolute302- not only did patients live longer and tolerate the therapy better than 2L chemo- they were also more likely to receive subsequent line therapy. That is indeed something to celebrate. Most importantly- this isn’t THE cure we’ve been looking for but this is certainly the dawn of a new era that we’ve all been anticipating for so long. Every therapy has AEs and will need fine tuning and real world experience before it becomes more tolerable for the not-so-fit patients in clinic. Drug pricing is also not an issue unique to this drug-it is a systemic issue that needs addressing on multiple levels. It’s so easy to be an “expert critic” for likes and engagement on social media and so hard to work towards moving the needle forward for patients.